1. Home
  2. CRUS vs BLTE Comparison

CRUS vs BLTE Comparison

Compare CRUS & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cirrus Logic Inc.

CRUS

Cirrus Logic Inc.

HOLD

Current Price

$119.53

Market Cap

6.0B

Sector

Technology

ML Signal

HOLD

Logo Belite Bio Inc

BLTE

Belite Bio Inc

HOLD

Current Price

$165.93

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRUS
BLTE
Founded
1984
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.0B
6.0B
IPO Year
1997
2021

Fundamental Metrics

Financial Performance
Metric
CRUS
BLTE
Price
$119.53
$165.93
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
7
Target Price
$157.00
★ $198.00
AVG Volume (30 Days)
★ 771.2K
177.2K
Earning Date
05-06-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 30.83
N/A
EPS
★ 1.47
N/A
Revenue
★ $1,997,379,000.00
N/A
Revenue This Year
$7.12
N/A
Revenue Next Year
$0.49
$492.11
P/E Ratio
$81.71
★ N/A
Revenue Growth
★ 5.34
N/A
52 Week Low
$106.26
$70.80
52 Week High
$180.42
$200.00

Technical Indicators

Market Signals
Indicator
CRUS
BLTE
Relative Strength Index (RSI) 51.67 47.82
Support Level $118.39 $147.34
Resistance Level $124.75 $172.02
Average True Range (ATR) 3.84 6.19
MACD 0.95 -1.21
Stochastic Oscillator 69.11 5.18

Price Performance

Historical Comparison
CRUS
BLTE

About CRUS Cirrus Logic Inc.

Cirrus Logic Inc is a supplier of low-power, low-latency, high-precision audio components that are used in a variety of applications, including smartphones, PCs, tablets, AR/VR headsets, wearables, home theater systems, automotive entertainment systems, and professional audio systems. The firm's products are organized into two streams: audio products and HPMS Products. These products include amplifiers, codecs, smart codecs, analog-to-digital converters, digital-to-analog converters, and standalone digital signal processors, Camera controllers, haptics and sensing solutions, and battery and power ICs. Roughly half of the firm's revenue is generated in China, with the rest coming from the United States, India, South Korea, and countries across the world.

About BLTE Belite Bio Inc

Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

Share on Social Networks: